{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', 'Q3W', 'Cycle', 'Cycle', '1 &', '1 &', 'starting', 'Study', 'Cycle 1,', 'Wk 42 (to be', 'Cycle 2-', 'Assessments', 'Cycle', 'Cycle', 'CX with', 'Notes', 'Day 11', '3 Day', 'performed', '3, Day', 'dosing 2', '4', '8-15', 'regardless', 'of dosing)', 'Calcium corrected', 'X', 'be applied per local guidance). The same modality should be used throughout the study (i.e.,', 'for albumin (serum)', 'if CT scan was used as baseline, participant needs to be followed by CT scans).', 'lgG, IgM, IgA', 'X', 'Plasmacytoma measurements should be taken from the CT portion of the PET/CT, or MRI', 'lgD/E20', 'X', 'scans, or dedicated CT scans where applicable. For participants with skin only involvement,', 'Bone Marrow (BM) Aspiration/Biopsy', 'skin lesions should be measured with a ruler. Measurement of tumor size will be determined', 'BM for MRD', 'by the Sum of the Products of the maximal perpendicular diameters of measured lesions', 'X', 'testing21', '(SPD). Imaging will be collected for independent review. For sites in Germany: Only MRI is', 'At the time of', 'allowed to be used as imaging modality for participants with extramedullary disease.', 'CR (always)', '19. Germany: no PET/CT to confirm CR or sCR will be performed until approval by the German', 'BM for disease', 'or at time of', 'Federal Office for Radiation Protection until further notice.', 'assessment', 'suspected', '(aspirate, preferred)', 'PD (only if', '20. Only required for participants with lgD/E myeloma, where serum m-component cannot be', 'not evident', 'followed otherwise', 'otherwise)', '21. Minimal residual disease (MRD) to be performed by the central lab at the time of first achieving', 'Only if CR', 'Bone marrow biopsy', 'VGPR or CR, repeat MRD testing 6 mo and 12 mo after achieving VGPR or CR (provided', 'have been', 'to assess sCR by', 'VGPR/CR is maintained).', 'achieved on', 'IHC22', 'this visit', '22. In participants achieving a CR, bone marrow biopsy to confirm sCR by IHC.', 'Biomarker', '23. sBCMA samples to be taken in all participants for GSK2857916 measurement during Cycle 1,', 'Soluble BCMA', 'X', 'X', 'X', 'X', 'Day 1 and Cycle 3, Day 1 at the following study times: predose (within 30 minutes prior to', '(serum)5, 23', 'SOI), at EOI (+5 min), at 2 h (+15 min) after SOI, and at 24 h (2 hrs) after SOI, on Cycle 1', 'cfDNA (plasma)', 'X', 'Day 4 (+1 days) and one sample at any time between Cycle 1 Day 8 & Day 15, with the PK', 'Optional', 'samples. Pre-infusion sBCMA samples are collected prior to GSK2857916 infusion during', 'Optional tissue', 'each of the first 18 cycles: after which, sBCMA sample should be collected every 3 cycles, i.e.', 'sample at PD for', 'X', 'pre-infusion C18D1, C21D1, C24D1, etc.', 'BCMA24', 'Genetics sample', '24. Upon PD- Optional tumor sample (BM aspirate clot, or fresh tissue, or tissue block from', '(optional)', 'extramedullary tumor) for BCMA expression analysis by IHC. To be submitted to central lab for', 'X', 'analysis.', '26']['2017N330177_04', 'CONFIDENTIAL', '205678', 'Q3W', 'Cycle', 'Cycle', '1 &', '1 &', 'starting', 'Study', 'Cycle 1,', 'Wk 42 (to be', 'Cycle 2-', 'Assessments', 'Cycle', 'Cycle', 'CX with', 'Notes', 'Day 11', '3 Day', 'performed', '3, Day', 'dosing 2', '4', '8-15', 'regardless', 'of dosing)', 'Treatment', 'Premedication if', '25. GSK2857916 administration: Study drug administration +3-day window. In case a dose is', 'X', 'X', 'needed', 'delayed, the participant should wait for the next scheduled dose to resume treatment. Please', 'refer to Section 7.2.2', 'GSK2857916', 'X', 'X', 'administration25', '26. Corneal management information:', 'Steroid eye drops26', 'X', 'a) Steroid eye drops administered as prophylaxis (such as: prednisolone acetate 1.0%,', 'Preservative-free', 'prednisolone phosphate 1%, dexamethasone 0.1% or equivalent) 1 drop QID starting 1 day', 'X', 'X', 'artificial tears 26', 'prior to each GSK2857916 infusion, and continuing for a total of 7 consecutive days. If dosing', 'Health Outcomes', 'delayed for a non-corneal event, the prophylactic drops can be stopped.', 'PRO-CTCAE', 'X', 'b) Prophylactic preservative-free artificial tears must be administered in each eye at least 4-8', 'NEI-VFQ-2527', 'X', 'X', 'times daily beginning on Cycle 1 Day 1 until end of treatment.', 'OSDI27', 'X', 'X', 'c) At the start of each infusion, participants may apply cooling eye masks to their eyes for', 'EORTC QLQ-C3028', 'X', 'every 6', 'approximately 1 hour or as long as tolerated.', 'weeks', 'd) Selected sites will participate in an ocular sub-study.', 'EORTC QLQ-', 'X', 'every 6', '27. NEI-VFQ-25 and OSDI will be administered every 3 weeks even if dose is delayed. Additional', 'MY2028', 'weeks', 'assessments may be conducted for those participants who are experience a worsening in', 'Patient Interview', 'X', 'visual function. Participants who discontinue participation in the study will continue to be', '(PRO) 29', '(within 21', 'assessed during follow-up until resolution of visual symptoms. Continue to follow up with', 'days after', 'participants via telephone who are still experiencing visual symptoms even after', 'C4 Day', 'discontinuation', '1)', '28. EORTC- QLQ-C30 and EORTC QLQ-MY20 should start at week 7 and continue every 6', 'weeks.', '29. Patient Interview (PRO) must be conducted via telephone within 21 days (+7 days) following', 'Day 1 of the fourth treatment cycle (C4D1). The second patient Interview must be completed', 'within 21 days (+7 days) of the participants end of treatment visit, unless the participant has', 'already completed their interview following C4D1 within the prior 30 days', '27']\n\n###\n\n", "completion": "END"}